RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
HJB, a China based-bioprocessing specialist, will merge with MabSpace of Suzhou, a discovery/development biotech, to form Transcenta Holding. The new company will have a pipeline of 10 innovative molecules. It plans to use HJB’s capabilities to shorten the timeline from target to BLA, using its next-gen Hangzhou GMP facility to support development of in-house and partnered molecules. Dr. Xueming Qian, former MabSpace Founder, Chairman and CEO, will be CEO of Transcenta, while Dr. Jonathan Yining Zhao, Co-founder and CEO of HJB, will be its Executive Chairman. Financial details were not disclosed.
Source: China Biotoday
